[1] Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS: Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol 2019, 10:144-54.
[2] Hacking SM, Chakraborty B, Nasim R, Vitkovski T, Thomas R: A Holistic Appraisal of Stromal Differentiation in Colorectal Cancer: Biology, Histopathology, Computation, and Genomics. Pathology - Research and Practice 2021:153378.
[3] Alexander W: The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge. P T 2016, 41:185-91.
[4] Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-9.
[5] Byun JS, Gardner K: Wounds that will not heal: pervasive cellular reprogramming in cancer. The American journal of pathology 2013, 182:1055-64.
[6] Ha SY, Yeo S-Y, Xuan Y-h, Kim S-H: The Prognostic Significance of Cancer-Associated Fibroblasts in Esophageal Squamous Cell Carcinoma. PLOS ONE 2014, 9:e99955.
[7] Kemi NA, Eskuri M, Pohjanen V-M, Karttunen TJ, Kauppila JH: Histological assessment of stromal maturity as a prognostic factor in surgically treated gastric adenocarcinoma. Histopathology 2019, 75:882-9.
[8] Cao L, Sun P-L, He Y, Yao M, Gao H: Desmoplastic Reaction and Tumor Budding in Cervical Squamous Cell Carcinoma are Prognostic Factors for Distant Metastasis: A Retrospective Study. Cancer Manag Res 2020, 12:137-44.
[9] Zhai Q, Fan J, Lin Q, Liu X, Li J, Hong R, Wang S: Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. PLOS ONE 2019, 14:e0223325.
[10] Nearchou IP, Kajiwara Y, Mochizuki S, Harrison DJ, Caie PD, Ueno H: Novel Internationally Verified Method Reports Desmoplastic Reaction as the Most Significant Prognostic Feature For Disease-specific Survival in Stage II Colorectal Cancer. The American Journal of Surgical Pathology 2019, 43.
[11] Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA: Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine 2018, 379:2108-21.
[12] Bertucci F, Finetti P, Mamessier E, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D: PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology 2015, 4:e1002729.
[13] Huang X, Zhang X, Li E, Zhang G, Wang X, Tang T, Bai X, Liang T: VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. Journal of Hematology & Oncology 2020, 13:83.
[14] Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33:459-65.
[15] Qureshi A, Pervez S: Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc 2010, 60:350-3.
[16] Henke E, Nandigama R, Ergün S: Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Frontiers in Molecular Biosciences 2020, 6.
[17] Seifert AM, Zeng S, Zhang JQ, Kim TS, Cohen NA, Beckman MJ, Medina BD, Maltbaek JH, Loo JK, Crawley MH, Rossi F, Besmer P, Antonescu CR, DeMatteo RP: PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res 2017, 23:454-65.
[18] ElTanbouly MA, Croteau W, Noelle RJ, Lines JL: VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Semin Immunol 2019, 42:101308.
[19] Loeser H, Kraemer M, Gebauer F, Bruns C, Schröder W, Zander T, Persa OD, Alakus H, Hoelscher A, Buettner R, Lohneis P, Quaas A: The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. Oncoimmunology 2019, 8:e1581546.
[20] Shang B, Liu Y, Jiang S-j, Liu Y: Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Scientific reports 2015, 5:15179-.
[21] Choi JW, Kim YJ, Yun KA, Won CH, Lee MW, Choi JH, Chang SE, Lee WJ: The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression. Scientific Reports 2020, 10:14372.
[22] Tan Y, Trent JC, Wilky BA, Kerr DA, Rosenberg AE: Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Therapy 2017, 24:130-3.
[23] Stålhammar G, Fuentes Martinez N, Lippert M, Tobin NP, Mølholm I, Kis L, Rosin G, Rantalainen M, Pedersen L, Bergh J, Grunkin M, Hartman J: Digital image analysis outperforms manual biomarker assessment in breast cancer. Modern Pathology 2016, 29:318-29.
[24] Dimitriou N, Arandjelović O, Caie PD: Deep Learning for Whole Slide Image Analysis: An Overview. Frontiers in Medicine 2019, 6.